Prospective study of 2,468 hospitalized COVID-19 patients in Iran, showing no significant difference with NAC treatment. IR.MUQ.REC.1399.013.
risk of death, 11.0% lower, HR 0.89, p = 0.43, treatment 65 of 309 (21.0%), control 274 of 2,159 (12.7%), adjusted per study, multivariable, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Pourhoseingholi et al., 5/26/2021, prospective, Iran, Middle East, preprint, mean age 57.9, 11 authors, study period 2 February, 2020 - 20 July, 2020, average treatment delay 7.4 days.